Definium Therapeutics (DFTX)
Develops lysergide and R(-)-MDMA drug candidates for anxiety, depression and autism.
Something off on this page? Send us feedback.
Develops psychedelic- and empathogen-derived drug candidates for psychiatric and neurological disorders, led by Phase 3 lysergide tablet DT120 ODT for anxiety and depression and early-stage R(-)-MDMA candidate DT402 for autism. With no approved products or product sales, the business depends on clinical and regulatory success under controlled-substance rules.
Develops investigational medicines derived from psychedelic and empathogen drug classes for psychiatric and neurological disorders. The pipeline centers on DT120 ODT, an orally disintegrating form of lysergide tartrate in Phase 3 programs for generalized anxiety disorder and major depressive disorder, with a posttraumatic stress disorder study planned. Positive topline results have been reported from pivotal anxiety and depression studies; additional studies in both conditions continue.
Also advances DT402, a proprietary R(-)-MDMA candidate in an early-stage autism spectrum disorder study. Operations are centered in the United States, with global headquarters in New York. No product is approved or generating sales, making the business dependent on clinical results, regulatory approval and commercialization. Both lead compounds are controlled substances, adding registration, handling and scheduling requirements.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 15, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $64 | Target: $78 |
| Sep 15, 2026 | UBS | Reiterate | Rating: —Target: — | Target: $70 |
| Sep 15, 2026 | Robert W. Baird | Target | Target: $75 | Target: $79 |
| Sep 14, 2026 | Oppenheimer | Reiterate | Rating: —Target: $70 | Target: $75 |
| Aug 14, 2026 | Maxim Group | Reiterate | Rating: —Target: — | Target: $55 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.08B · Total debt $36.5M · Total assets $1.11B · Shareholders' equity $918.7M
- Revenue
- $0
- Operating income
- −$75.1M
- Net income
- −$159.0M
No dividends on record.
| Institutions | ≈ 83.90% | 112.74M shares | |
|---|---|---|---|
| 388 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 3.41% | 4.58M shares | |
| 12 holders · as of Sep 18, 2026 | |||
| Other | ≈ 12.69% | 17.05M shares | |
| remainder | |||
134.37M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.36% | 11.23M | as of Jun 30, 2026 |
Avoro Capital Advisors LLCInstitution | 5.35% | 7.19M | as of Jun 30, 2026 |
Driehaus Capital Management LLCInstitution | 5.09% | 6.85M | as of Jun 30, 2026 |
Jupiter Topco LLCInstitution | 4.18% | 5.62M | as of Jun 30, 2026 |
Capital World InvestorsInstitution | 3.99% | 5.37M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 3, 2026 | Robert Barrow | director, officer: Chief Executive Officer | −19,023 | $37.94 |
| Jun 25, 2026 | Matthew T. Wiley | officer: Chief Commercial Officer | −2,867 | $45.03 |
| Jun 25, 2026 | Daniel Karlin | officer: Chief Medical Officer | −10,035 | $45.03 |
| Jun 25, 2026 | Robert Barrow | director, officer: Chief Executive Officer | −29,208 | $45.03 |
| Jun 25, 2026 | Brandi Roberts | officer: Chief Financial Officer | −3,013 | $45.03 |
- Helus Pharma
Phase 3 psychedelic MDD therapy with FDA Breakthrough; Phase 2 GAD program
- Compass Pathways (ADR)
Psilocybin COMP360 on rolling FDA NDA for TRD; first psychedelic near approval
- GH Research
Inhaled 5-MeO-DMT GH001 Phase 3-ready in TRD; ultra-rapid remission
- Axsome Therapeutics
AUVELITY is the only FDA-approved rapid-acting oral MDD drug; the launch bar
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Definium Therapeutics | $39.14 | −0.36% | $5.21B | — | — | — | — |
| Helus Pharma | $13.45 | −1.54% | $846.7M | — | — | — | — |
| Compass Pathways (ADR) | $15.00 | −0.07% | $2.03B | — | — | — | — |
| GH Research | $27.89 | −0.15% | $1.91B | — | — | — | — |
| Axsome Therapeutics | $204.68 | −0.39% | $10.57B | — | 1,221.2 | 13.6 | +44.2% |
| Median | — | 1,221.2 | 13.6 | +44.2% |